These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 3274451

  • 1. Potent immunosuppression overcomes retransplantation, presensitization, and historical positive crossmatch as transplant risk factors.
    Gaber AO, Thistlethwaite JR, Haag BW, Stuart J, Mayes J, Fellner S, Stuart FP.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1915-6. PubMed ID: 3274451
    [No Abstract] [Full Text] [Related]

  • 2. Cox regression analysis of outcome risk factors in 519 renal allograft recipients.
    Canafax DM, Savik SK, Draxler CA, Le CT, Ascher NL, Payne WD, Sutherland DE, Migliori RJ, Simmons RL, Najarian JS.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1947-8. PubMed ID: 3274455
    [No Abstract] [Full Text] [Related]

  • 3. High rate of success in kidney cadaveric retransplantation with optimal matching and potent immunosuppression.
    Hiesse C, Neyrat N, Busson M, Bensadoun H, Lantz O, Bellamy J, Benoit G, Charpentier B, Fries D.
    Transplant Proc; 1990 Aug; 22(4):1909-10. PubMed ID: 2389483
    [No Abstract] [Full Text] [Related]

  • 4. Positive B cell crossmatches in highly sensitized patients--influence of antibody specificity on renal transplant outcome.
    Lazda VA, Pollak R, Mozes MF, Jonasson O.
    Transplant Proc; 1987 Feb; 19(1 Pt 1):782-4. PubMed ID: 3547840
    [No Abstract] [Full Text] [Related]

  • 5. Triple immunosuppressive therapy in immunologic high-risk renal allograft recipients.
    Cole E, Robinson C, Bear R.
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2026-7. PubMed ID: 2652662
    [No Abstract] [Full Text] [Related]

  • 6. Cadaveric renal transplantation after pulsatile perfusion, histocompatibility matching, and conversion to cyclosporine therapy.
    Milgrom M, Kyriakides GK, Esquenazi V, Olson L, Miller J.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1873. PubMed ID: 3274444
    [No Abstract] [Full Text] [Related]

  • 7. Tolerance induction in human kidney retransplantation: impact of repeated HLA mismatches in 156 second renal grafts.
    Gnant MF, Sautner T, Rosenmayr A, Muehlbacher F.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):319-21. PubMed ID: 8438317
    [No Abstract] [Full Text] [Related]

  • 8. Quadruple therapy for cadaver renal transplantation.
    Deierhoi MH, Sollinger HW, Kalayoglu M, Belzer FO.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1917-9. PubMed ID: 3274452
    [No Abstract] [Full Text] [Related]

  • 9. A comparison of three immunosuppressive protocols in patients aged over 50 years.
    Fryd DS, So SK, Kruse L, Canafax DM, Sutherland DE, Simmons RL, Najarian JS.
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1530-1. PubMed ID: 3274374
    [No Abstract] [Full Text] [Related]

  • 10. Intermodal immunosuppression for cadaver renal transplantation: results using antilymphocyte globulin, azathioprine, cyclosporine, and prednisone.
    Halloran P, Ludwin D, Bear R, Aprile M, McQuarrie B, Poole R, White N.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1931-2. PubMed ID: 3274454
    [No Abstract] [Full Text] [Related]

  • 11. Effect of DR and DR6 matching on cadaver kidney transplant survival.
    Reyman TA, Toledo-Pereyra LH.
    Transplant Proc; 1987 Feb; 19(1 Pt 1):702-4. PubMed ID: 3274848
    [No Abstract] [Full Text] [Related]

  • 12. Strategy for improving retransplantation in the CyA era.
    Dickerman R, Langley J, Brinker K, Trevino G, Melton L, Vergne-Marini P, Wilson PK.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The results of renal transplantation with cyclosporine in immunologically high-risk patients.
    Dickerman RM, Vergne-Marini P, Langley J, Trevino G, Velez R, Brinker K, Nesser D, Long D, Hull AR.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1846-8. PubMed ID: 3079047
    [No Abstract] [Full Text] [Related]

  • 15. Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
    Stratta RJ, D'Alessandro AM, Armbrust MJ, Pirsch JD, Sollinger HW, Kalayoglu M, Belzer FO.
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1726-8. PubMed ID: 2652564
    [No Abstract] [Full Text] [Related]

  • 16. Potent immunosuppression overcomes immunologic high-risk factors in recipients of cadaveric renal allografts.
    Gaber AO, Thistlethwaite JR, Haag BW, Stuart JK, Mayes JT, Lloyd DM, Fellner S, Stuart FP.
    Am Surg; 1987 Jul; 53(7):407-9. PubMed ID: 3300451
    [Abstract] [Full Text] [Related]

  • 17. A controlled trial comparing sequential antilymphocyte sera and cyclosporine therapy to conventional therapy in renal transplant recipients.
    Cardella CJ, Harding ME, deVeber GA, Honey J, Cook GT.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1996-7. PubMed ID: 3079065
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Trends in immunosuppression for kidney transplantation.
    Butt KM, Zielinski CM, Parsa I, Elberg AJ, Wechter W, Kountz SL.
    Kidney Int Suppl; 1978 Jun; (8):S95-8. PubMed ID: 357820
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.